Teva Pharmaceutical Industries Ltd. $TEVA Stock Position Lowered by HighTower Advisors LLC

HighTower Advisors LLC lessened its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 6.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 183,535 shares of the company’s stock after selling 13,122 shares during the period. HighTower Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $2,821,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. US Bancorp DE raised its stake in shares of Teva Pharmaceutical Industries by 6.5% in the 1st quarter. US Bancorp DE now owns 10,812 shares of the company’s stock worth $166,000 after buying an additional 656 shares in the last quarter. Bfsg LLC raised its stake in shares of Teva Pharmaceutical Industries by 7.8% in the 1st quarter. Bfsg LLC now owns 10,960 shares of the company’s stock worth $168,000 after buying an additional 790 shares in the last quarter. Factorial Partners LLC raised its stake in shares of Teva Pharmaceutical Industries by 0.3% in the 1st quarter. Factorial Partners LLC now owns 333,000 shares of the company’s stock worth $5,118,000 after buying an additional 1,000 shares in the last quarter. Yousif Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 1.9% in the 1st quarter. Yousif Capital Management LLC now owns 55,986 shares of the company’s stock worth $861,000 after buying an additional 1,033 shares in the last quarter. Finally, Mackenzie Financial Corp raised its stake in shares of Teva Pharmaceutical Industries by 4.1% in the 4th quarter. Mackenzie Financial Corp now owns 29,889 shares of the company’s stock worth $659,000 after buying an additional 1,171 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $18.4660 on Friday. The business’s 50-day moving average is $16.75 and its 200-day moving average is $16.28. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The company has a market capitalization of $21.18 billion, a price-to-earnings ratio of -115.41, a P/E/G ratio of 1.11 and a beta of 0.62. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same period in the previous year, the firm posted $0.61 earnings per share. The firm’s revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Matthew Shields sold 6,206 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president owned 9,989 shares of the company’s stock, valued at approximately $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 65,001 shares of company stock valued at $996,958. 0.49% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on TEVA. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a “buy” rating and a $24.00 target price for the company. Bank of America upped their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Hsbc Global Res raised Teva Pharmaceutical Industries to a “strong-buy” rating in a report on Monday, April 28th. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Buy” and a consensus target price of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.